1. Home
  2. QH vs XCUR Comparison

QH vs XCUR Comparison

Compare QH & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QH

Quhuo Limited American Depository Shares

HOLD

Current Price

$3.35

Market Cap

10.1M

ML Signal

HOLD

Logo Exicure Inc.

XCUR

Exicure Inc.

HOLD

Current Price

$1.12

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QH
XCUR
Founded
2012
2011
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
9.2M
IPO Year
2019
2017

Fundamental Metrics

Financial Performance
Metric
QH
XCUR
Price
$3.35
$1.12
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
10.3K
★ 15.3K
Earning Date
10-27-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 83.37
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$44.02
P/E Ratio
$2.86
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.07
$0.94
52 Week High
$12.81
$9.48

Technical Indicators

Market Signals
Indicator
QH
XCUR
Relative Strength Index (RSI) 33.75 43.50
Support Level $3.00 $1.05
Resistance Level $4.07 $1.48
Average True Range (ATR) 0.27 0.09
MACD -0.00 0.01
Stochastic Oscillator 30.57 50.70

Price Performance

Historical Comparison
QH
XCUR

About QH Quhuo Limited American Depository Shares

Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services. It generates maximum of its revenue from the on-demand delivery solutions segment.

About XCUR Exicure Inc.

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Share on Social Networks: